<SEC-DOCUMENT>0001193125-13-132663.txt : 20130328
<SEC-HEADER>0001193125-13-132663.hdr.sgml : 20130328
<ACCEPTANCE-DATETIME>20130328171926
ACCESSION NUMBER:		0001193125-13-132663
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130328
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130328
DATE AS OF CHANGE:		20130328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		13725059

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d512062d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) March&nbsp;28, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. Pharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
March&nbsp;28, 2013, A.P. Pharma, Inc. announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its lead candidate, APF530, for the prevention of Chemotherapy-induced nausea and vomiting. The
Complete Response Letter describes certain issues that must be addressed by the company prior to approval of APF530, as described in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, Dated March&nbsp;28, 2013</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: March&nbsp;28, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d512062dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g512062g79f08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Receives FDA Complete Response Letter for APF530 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- Company Revises
Projected Launch Timing from 2H 2013 to 1H 2014 - </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- Conference Call to Be Held at 8:30 a.m. Eastern Time -
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; March&nbsp;28, 2013 &#150; A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today
announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and
vomiting (CINV). The CRL describes the following issues that must be addressed. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to chemistry, manufacturing and controls (CMC), the FDA has requested the refinement of one product quality analytical test method, and
that certain deficiencies identified during facility pre-approval inspections be addressed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has requested that a human factors validation study evaluating the usability of the APF530 syringe system together with its proposed product
labeling and instructions for use be conducted with product assembled using a validated, commercial process. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to clinical, the FDA has requested a re-analysis of the existing Phase 3 clinical data that reclassifies patients into those receiving
moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC) according to the recently modified ASCO 2011 Guideline. The FDA did not request any new clinical studies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We appreciate the FDA&#146;s thorough review of the APF530 NDA,&#148; stated John B. Whelan, A.P. Pharma&#146;s president and chief executive
officer. &#147;While disappointed in today&#146;s notification, we believe that the issues raised in the CRL are addressable, and we remain firmly committed to the successful development of APF530, which we believe will fulfill an important unmet
need and improve the lives of patients suffering from CINV. In order to allow us time to carefully address the issues raised in the CRL, we are now projecting product launch for the first half of 2014, versus our prior guidance of the second half of
2013.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more
-</I> </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Receives FDA Complete Response Letter for APF530</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 2
</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference Call Details </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma will host a conference call on Thursday, March&nbsp;28, 2013 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Interested investors may participate in the conference call by dialing
(877)&nbsp;856-1964 (domestic) or (719)&nbsp;386-0001 (international) and use participant code 135738. In addition, the live conference call is being webcast and can be accessed on the &#147;Calendar of Events&#148; page of the &#147;Investors&#148;
section of the Company&#146;s website at www.appharma.com. A replay of the webcast will be posted to this same section of the website available approximately two hours after the call. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s lead product, APF530, is being developed for the
prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one
injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company&#146;s proprietary
Biochronomer&#153; drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the
prevention of acute-onset CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products
using its proprietary Biochronomer&#153; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or
twice per day to products that need to be injected only once every one or two weeks. The Company&#146;s lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P.
Pharma resubmitted its New Drug Application (NDA) for APF530 to the U.S. Food and Drug Administration (FDA) in September 2012 and received a Complete Response Letter in March 2013. For further information, please visit the Company&#146;s web site at
www.appharma.com. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more
-</I> </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Receives FDA Complete Response Letter for APF530</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 3
</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This news release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties,
including uncertainties associated with the potential approval of APF530 and the potential timing for such approval, if approved at all, the projected timing for the commercial launch of APF530, if approved, as well as risks relating to capital
resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, successful launch and acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings with the
Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact:
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone:
(646)&nbsp;597-6979 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: mrice@lifesciadvisors.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President and Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>### </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g512062g79f08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g512062g79f08.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0"S`P$1``(1`0,1`?_$`+D```(!!`,!````````
M```````)"@$&!P@"`P4$`0`"`04!`0``````````````!P@!`@,%!@0)$```
M!0,#`P$&`0@(!04````!`@,$!1$&!P`2""$3"3%!42(R%!5A<8&Q4B,6%PJ1
MH<'A0G(S&-'Q8H(T)$4V-S@1``$"!0,"`P8#!@0%!0$```$"`P`1!`4&(1('
M,4%1$PAA<8$B,A61H13PL4)2(Q;!8H)$T>$S4Q?Q<F,DM#7_V@`,`P$``A$#
M$0`_`)_&B"#1!!H@CSI)XUCVZKY\Z19LVB*KATZ<J%1;MT4@`QUEE3B!$TR!
MZB.J:J6&T)4IU1D`!.9@+J64%QTI2T-2292A5?);S'</./*DG"(W2XRG>C`@
ME^QV$E]S8`X`#;D'DXB*K5J9(W0]2C33<PWA+.LN"'T4XIZ-2A-;GRR'\P!U
M(_"$[FO.6!X8AWSJCSZUM)(;;^8DCM[(3[>O\Q;DB0>."X_P5!1$=N'Z4T_(
M(RJO:W"!15*B#>IA#K[.NGM:O26'/_[-?IWV"7[XCQ=/66DKE9[2XX.Q6HC3
M\#%DL_YA3D>50HGQOCM,I#`*B(,S(F4(%-P%5^NHGNZ]1#IK<N>DG&&TE3%;
M4%?B92_='CI?6#<WU;*BA;;7W25#I[_^4,EX;^=C#F<;GB<>YJMM?$-VS+U.
M-BYY1TD]M&0>.#;6Z;E^0B:<;WC?"43F-41#26Y`].^1XI3&[4#R:R@;!)2D
M24!_B8<W'OJ0Q3,JU-IJT*I+DL@#=+:H^PZ0^ANJ1PD@Y;G(=!QVETE$QW)J
M)*!O(<A@Z"4Q1J'OU'TME*IK$ECJ.XB1R%-N)FDC;*8(Z&/0U6*P:((-$$&B
M"#1!!H@@T00:((-$$&B"#1!!H@@T00:((H(T#H%?Z`_3TT3`U)D(#/MK'4J?
M:4!`P@.X.@"7KT]`KJFY`^L@""92)RF3VC3KF3S:Q)PIQBO?^3GQG$H\!=O:
M-D1BJ(W'=4DF0=J#-N<3'39%'JHY$@HDIM$=U-=9A>%7K/+HFU6%"U#<`MPC
MY4#QG*7_`!CC<VSBRX#9UWB_.)2D))0@$%2R.P'6(:W,GRP\GN7!7L`ZG28S
MQJY54(C8UF.W;)PZ9;OV87%*$5,LZ=B2@'[*I$Q&M`IKZ#\;\`XCB;:*JXH%
M9>DR)6N12D^"4]A[X^<')WJ2RS+E*I+,\*2T*F`E`(7+Q*NAF/"%@*.553%.
MJ<3G*`@*J@B=4]>ICJJFJHJ8?:)A&NGXBWTC38;90$-@S`&@TZ1'&INM?5K\
MRI<4MS:1,F9U[Z]XH0YB"8Q"]3!01`!]`ZT]P![=9/*3*7:/,W4UC2MR)[H[
ME%Q,6A@#>4``>E!"O6GYP]^J(;`,A],6.O5+KA6X/GEX=/\`U$?2D`*HI)I"
M)%@71.BLF82+(+IT.DH0Y1`Z9DE"@(&"E*:UMQI6W4>2XD%A6B@1,*!ZB.CM
M504>6MDD58<2$+!(4DR)[>T=8GI^'O.T]G;@_CJ7NAP+F<Q_*S^*7SU159TZ
MDTK)49M&<F]45.=11Z[1<AO-Z#MU\LN:L8IL8Y*K:2C3MI7?ZC:>P2N9D/C.
M/K1P5E%7E7&U%65ZM]<P5LNJ/=3<A/\``Z0TPJQ#@(@:@>G4HE]?3UZ>NE>4
M+!U$-X+2H:3CB<YP$0((&&@"4.E1]/ZM8'2L%.W376*CH?&4+TSWY*,$<?.0
MEF<:+L1NF3R1>PQ16",%&J.F34\R9/Z%-VL5)3:)TU-X]?E`=,&R<=Y#?<??
MR>B2C[53SWE2@.G60[QPUZY"QZR9#2XO6J6+K5?],)$P3[3V^,,)!4VTNT0,
M8P`8Q3=#``@`T*'2M`_+K@5E0.U()GI,=![8[I)2HC4`'QZQVAN`=PFH40ZE
M-0-H_@/35AWI]L5V_-H=(ZRJB8QJ&J`>E*=/^.KQYID9"7Q@*`/J5KX13NT$
M0[I1-[C`(%#]&JG<D;E))'LBTD=$Z>^*BJ!0ZG`/7<(]`#_)7^_5LU]0A6O3
M_G!O'<ITZP"J80Z&"NZA0`0&H^X1J/35$K*M5(6D#K%-P'0I,^D`G4%,#5(4
M:A4:U`?\H@/IJOF-I&Y6Z1]D5^:0EMG[8Y"MM$I3%IN#YP$-H"(?CZ:J2D]Y
M`])Z0&8EW\9=HHJ=4H%%/8(>@B<0_L$*C^35?D2@J63%#YA,FP#!WB@<"B;V
M=1H(!6E>AAZ4U9M</SI!+?PG^$'F('RJ/S_E'+<:GS!\E?0?UOF_)35_F)Z[
M5>/3\O?!KXCI^QCDK_IG$.H@41`/3T"NJ+"2F2_IB\$@S'6-#N?G-VQ^#^%7
MN1+B*C+W?*BO&6%:)7!$W4S,?3&.5=5,![I8M@(@HN<`_P!,!`HB;IKON/N/
M*SD:_)M5+\M&TG<XO603"YY*Y`H^.\;<O59\U0H[6T"4RKL)?M[8C5O>$?+G
MGP[C^3W+W/F.L-QE^MT_X=M[YG63<H0;LQ5632T8E-T=JTCDR'3(8Y4TU%#!
M53XQ'4KK=R5AG%Z?[6PZVO5]6Q,/K:3J5#KN40)]^_2(GO\`%V;<I,JS'.KP
MW;J&I`-.VN12E"M0`#H"9B<HT4YQ^/;)W""1L\;LG[=O6S+X34/;=\VT9<6#
MU8@IU;+`J!0WG!4#$$H;3%Z@(AIR<6\OVGD5=0U24[E/64X&]M<IB<Y=/<81
MW+_"=9QPS2/>>V_;WU$)>`E,G4Z#L(T!,@H"XHI_$:HE*80Z5_$!Z4ZZ<*ZF
M2"2G0)G"&31.?J@RV=QW2$AU,.*QGX;LNY-XXX^Y&MLG6-;,/?*;!\,1=2QX
M<D#"NGZK-U*/W[GZ=L<K9)`ZA2%.)STH`#Z:C/?/4G9K-E51B9MU2]54ZE#<
MB1"BD3D`-=9RUB7EK]+=;<,9I<E-Q;;34!!*5``(2HR49GP$>OR9\-E]X5P3
M(Y_QEF:S,[6I`-B/+I1M,4W:J+$!32</8YVT`S59%HJ8=Y1.*@%*-0UCQ/U)
M6Z_Y&WCMPME10/NJDA3IE/X3B[-/3$_8\6=R"U71NN0R"5)0D=`.LP.PA,:2
MJ*::IVZP+@9,%$3DJ4#%H`[Q$:&``K[-24>J-^TI$U$].O7O[HB+-JWNJ:W%
M:M""-!TE(SD0=>T3`?%SD5#AUXC;SS_=\8H]3CKLR7?T;#'4%JI<B+UQ&!!L
MVBJFT-\D9(VTP#0:=!U\[.8[8K.N>&<=I'$H4X6Z92NH0HSF3+LGO'TVX-N2
M<!X".4W)M;C*4NU6P$!:D$)"4C=IN,CUBT7GGRNR?L5*X\8<1KRN*39=U6Z7
MCM.6<VA!LDTP5+NDXE-<QU^OQ=1(4/=KU/>FU-'=3;*^]4;+TOEW*(*CX2ZQ
ME1ZD5U]I3=K18K@]3DF8`22@`=209&?LG#3?'CSWM/GGC"9NV+@C6A>-G2J4
M%>]J*N`7^WR"[<CQ%5@<PF658*-U2AN,(B!Q$!ZZ47)''=RXXNR+96+2^RXG
M<AQ,Y'V:_C#8XRY&H>1K,JZ4[+E/4(5M6TN6Y)]LM(CE\I.05GM_,U-9=E;:
MG[^@,3N[4:1-HVJU7DYB>N.W;=<PRD:U0036V[I$0,<1``+M'K6FI.XQCE4Y
MP"U;D/,4WZMQ:E+<,I)69]>\@8BUE^34B?4.*]QE^I=H&@E#;>I4KJ-.@]YA
MEW'+S.WSD;E/97'7,O&]SB0,D3\;;MIN5GDJ6X&;^6(L>(4FV4J)4RM7H(&Z
MH@/II3Y#Z?E6;!ZG*;!<F:QFE;+BP@S!`END?$0W<>]08NF>-8C?K556]ZK4
M&V2Z$S*E?2)))^H]^DX81SMY\6]PIMJV%'-@79D6]KZD%HBSK8MN/<NDG3Y$
MB9]T@[22.1),05``(4W<./H&EMQW@=5G=2ZT*AFFIF$DN..&02/V]D,WD'/F
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MMI&)+B\Y&2`Y!Y6PKCCCHRR,A;-RSUKXY6MYY//)FZ'T7VTVLA+H(`9FQB_J
M##WCD$M"^FM_3^G^D<QFW9->+JW24=4TE:M^A`(G+IK/XQS=1ZB*Q.6W'$K+
M:GJVMI'%H!;VE/RD@GKI*7>+'QAYW<RPF0;GQOR%XUBVNAL=S'P=IV*K-.;J
M2NH""JQAY%A(%V_1KBJD4QTP$Q0/7TZZVEU]/%B=LS5_QNZ(^W*(\QQV>P#H
M2)?E&OM7J,O35W=L63V=X71,_+;:^I1`F`9]_P`H]&W?-#RKA^3>.L4YRXV6
M_C6"R!.1S!.`7>S@70SB)=VFS9RC<'?_`*-91-5PGW0,;:`U`-8%\"8O5X=5
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M&6L?J5:;1_5`_P`T]._:)$W\4TJ4^V+?_2G\5J]P/]+=N^U?-_J>S=_7J-?V
MBH_[G^[\C_5_-$G?OZ/^U_L/U7P_DB[\I9"M;%>/[LR'><BG&6U:,*^G)9V=
M4J0D:,43+*%3$1#>L8"T*4.IAZ:\]LMU5>:]JV4*2NJ>4$I`UZQ[KK<*6T6Y
MZYUJ@FE905*/@!$"#/67L_>4+EF#&U8U[<#FZ)Y_"8LLQ,ZGVZWK7:*;%'JQ
M1$2)-B,BF=NEA#=VCF``-2FOI'B%EQ3AS`!<*K:VX&MSREZ*4N4]H[RGVCYC
MY=D>9<U\A?9[0%*H`Z0U_*E(,MY[`D:"&#W)P\X@8:N/%N'.<'+?)6;<OQRT
M%;T%@+%RHOR6$>:E&*[5H@]*\;*-6(O%R&$:`8J0"(ETFO[YRO(*"OO^%V.D
MI;$$*4Y4.H"5+$B"I)EJ)>W6'XC`,4L]10XYG5_JJJ];T!JF0ZHH200=I0#*
M8EU/81=_\P#<$1;#7C'QOM4BI8ZR[74D?I55E7THU:,/H&,*DZ5$IE57`L2B
M)AZF,-=9_2M3/U%?=;[4A*4N+3)0T!(F5#W`F4:KU;/,BV6O'Z8$K;,Y=2E)
M$ID>Z([EMP\C/71#VTU;.?K9^890[0JB"J:@N'RI$T@+W"%,(U#I2NI@W>X,
M(L]34M+1_284J8.@*1WB%-BH:H9+3T+C;O\`5?2F120=JR`")R.G6)'_`)JK
MO_A)QPX<\5[:EW46@A!(2]RL&[H[=!]'(0"!FR4@@003<()2P*F*!@$`&HZA
MAZ>+2G),PO&4W-*7'VUR!4`02M9&D^\I1.;U'7FKQK#+)B]F<4TVZ!OD2"$M
MH2LSEXDG3OK%R\!Y*0POX>N2^1<B`HTLNZC7"-CL9<HHMBL'\0-H@$6R5H;:
MO<"XJ%*0M3&^(/?K7<EHM]TYQMM+94I*FMH<#?90429RC<\?/UE#P77U5Y44
M%U"BCS--"G24^L^T1NL,8HNK+V0\=XELR#DI&Y+SDX:WV[8(YTF?:N9,'[I0
MRR*94V[=HFH8QZT`P!J85_R&AQS':B[O/-I-+3F7S#54I!/OB#^.8A5Y9F+-
MHI*=Q3=0ZC<=IT$YE>O\.D2G/+^2!XL^-O!G%FWW0`+J7Q[;I3U`JLA`6<13
M]X%#E*'[59ZH^3$YO?J$W`S:\QY=J\LK9K0&7G9J_A6#\I]AU('NB=_/;E/A
MG$=#BE'M;:54,,E(ZEN2MP'Q&OOC>GB':]E\<_%A9#F\HZ#BD&6"9.X;S,^!
MLA]]?N&\L^,F^,;_`,QR[:&32*4=QAZ!I<9E=:[+^7:FII%NJWUX#:4DDI2E
M03H.PT)AFX!;:##>)J%BX!H%JB*G%*`&XJFK7X$#W"%R^!IDYMK'',;D,=H+
M*U0F[E<PB1@419OF,6T>7FFNU`Q2D400:$*@)B]`VT]FFWZD:FFJKW9<=1K4
MA#6^7U:I2D@^V<X5OIQ15-V:]9"I.RC<?>4V2))("E$$>R0CS?!Q8T?F;D/R
MSY4S\:UE%U[V=M[;?/$".`8'NYTXN4B[!18HBBNU0JD4Y>H%$0Z:\_J!K%VC
M&;)B5(X6VT4OSH!EX2)`\8LX"MM-><EON6UB`]5*K-K;A$]$@@@'V&/!C"K<
MF?/45^0"N(C!`*31W:9Q,@5?&"8,3%4,-2F.926#;[:Z]E258=Z;%)!4';FZ
ME*IG4-N3)D/<-?9&N6R]EOJ@IG'DC]);:5QQN0T\Q&W;N/8S.D;9<L?(3EK*
M')AUPZX/8?LK*N4;$D%37-D:^(UM,0./KAC4TUG:\>T=I+,E"Q954S*.*@8O
M^$!$-<=AO&]KM&)G-.0:Y^BM%0/Z3;1*5.I/T[I:D'73PZQW&9<E7VZ9;_9G
M'M!3UUTIR?.=>^AHCJ`9&1$*0Y46YS%R#S8XUX&Y9Y;LW*U]&NJU+M^S8Z9M
MVL':C,MQL/O$>0C,B8`Y^TIF%2I`,!!$!TZ\/K\-MG&MTR/$*%VG8+:D;W-"
MY(&2O;KWA(Y;09Y<N2[5BV7US53YBP]M;2),:CY9]2.VL,%_F`+M(M%<3.,L
M$`D6N2^XZX$&Z-16^V,7R5DII%I4Q"IIR0T$`]^EUZ:VZ1AZ^9?6=&:91W?P
M@J^;3V[I0R_4A5/!G'\1I%%:JJL0C8/J4D"1)]D@9PVJ+QYBO@SP[N:6M:S8
M&W'6.L2R<M/2#5H@B]DYE&)^G>/Y)^5,BSI9P\6W")A'ITTBGKG<<XS(4BWG
M7W'ZX)0E1)T*^P\)0[6[=9,#PUVIIF&Z=FGHE*4I(`U">Y\9PF7^7OQ^1PKR
M2Y$W2T0>/',HG;<?/O42G.P=,Y&4>W"+-R<!%$SEJ\0*KM$-P%"NG]ZH+@&5
MV7"J-2D!AALR!DGYI!.GP,1T]+-H4O[WF]8B;M0\I,U#YMR25J,_;,3^,8X\
M93!YR=\K'(#/5P,$)2,M5_=$XT<+)@LBD\=/'-HL5"&.`AW$OMQ#E'U`=;/E
MBI5BO"MHQN9:?JD)"PG0Z?-^8,7<2!>7<RWW(E("Z&F?4&U$3'0)T]Q$4S#W
M>4OG>LNTSKED+,QA+0S$5DA[XMF<;;QYIV`#U*4"W&T`@]0H/XZK8-^'>GBI
M>=']>J*@`>I#G0S[RG'DO@7F/J-I&F)"FH$`J]A"M9CVCI&Z_+GR,YOR%R5'
M@_P@M"T9[)*#PC2XLB7PU0DX"W)-,QR/UVK%X11F*$$8#$6<=%$E1*!0$!$0
MX#"N+;%:L0.=Y\^\W:RF;;2"4EP=0"1K)7A#,S7DZ^77*3@/'S3+EU`.]QP:
M-R,BH3$IB$O\^L?\HG/(?"7&_D1R#-G*_;Q?V^9&-ABD+;=G/KW=&;I-(Q%%
M0:K+C&B!A.F0VPI1Z@(:??&UVPU&%WK+,:M?VYAJG6`L]7"!X]^OCU,1VY:M
M.=NY':L.R*["XN/U34TI0E);2M0W`@'73I/L(F5_N"X_4-_^?_W`]`_\G]3_
M`#Z@G]W3X_[OSXGC]I__``>1"@/Y@;,C^Q>-5B8TBY(S!SER\S%?))'$BKR'
MM!-K(/V0B`@/T[I-]M.'^(`T]O3#C3=VSI^Z5"=U/0L`I]BR2`?RA#^J+*OL
MF!-VIMS94USI!'\S:`"L?$&(YGC<Y5VOPYY'P&6KWMYY/6DG%24'(_:F_P!3
M*Q";Y%9--]'(``F-M[U%`#U*%-2YYHP>LSW$_M%I<#56E86`3(&6LC[S$/.!
M<^1@.0KO%\;W61:-H6!-2=?J^`[PRF>YV>+6W>3ZG)&U<(9'R+?5T3J$Q=5P
M789T,+;)F[<Y492VK9<H*%4D2K;:@5;H(U]FD-1\8<V7'$7,5>KFZ>V(;V)0
MD@%8\"H=.DO;$@KAS#P=1Y8G*Z:D54W%U04IW:3M/8@1JUGCG7A[._D4QWRB
MNNW)FXL%6<ZM85[/E(85Y&1:0L,_8/&"T.J8_?0<NG)%!W5*<Q`$0$-=]B_%
M62XSQ(]B-M<#.4N%1\T+EHH@_6.F@C@LCYBQK).2Z;+ZQI3N*TRD@H*)J4I(
M(^GN!'M,<C8HYI>4SC0YP7C-#'>*DKLQRFXM5.&3AU#A:KYXYNJ3>LTR@40>
MHO42[J!4J85J-1U8FRWOC?@V](R:K4_>'674A9452+@`1(DS[$^^+E7RT\I\
M^6=['J8,69E;*B"@))\DE3FX"78@`^$,DY[<Q.!DERCNO$G++CZ]OA7"QV<1
M;%[6R51V^$_:;KKVY*-D2"8&)4W/RB/J80TE^,\`Y+.)ION#W#R?UJB'$+.W
M_4"?QAZ\G9SQFC)39<VH!4KI`%(4E.Z7;;[)]/="K^77D;9<F9O$F+;3L-?&
MG%S&-X6V^CL3VZW$S^\4(R;8]EK)E0`AG:3]NB"16HDKW5*[A'3JPOB!W$K;
M6W>[50J,RJ&5SJ%G1!(.HGTEUG"*SKFBW977T>/T=.Y3XHP^W)AM,BXD%,@0
M.TP(EV8%PYAFXTK`Y`QF$([%EV_NPJVMZ%<QR+.2@8>840>HJN&Y4D^Q**)E
M+U$-R=1+J$5_O>1L5%38'[D[649>)62HE)(F"![(G)8+/8WJ>FO[5O:I*ORI
M(DD;@DRE/3K[]80%YOY:0SISCXO\6(MP)EFK2+30;)E$PED\EKBBR76(`_&H
MD6%W%#V%_+J3?IX#>-\?W_.'FTS;;.R?110)J3\29>^(I>H\JR7DC'<&:63O
M<2I0'8J4D(5\-3[HR5)>)KR"Y$:P^#\I<M%GG&ZWSM4&90EQ6?.XE)--1)DM
M;Z94U6ZS05#D)54P!M`>M=<ZWS3QE;W?O]NQY",I7,[P!M\P_P`1'A^Z.SJ>
M&>2KFRC'[UD"E8F@;2V!)9;_`)-T_>)RU$.-D.(C3'O"J:XL<;G#6U7)K+>6
MG%3DI0XNUI5!9M,R,JMM(9PL]3=K4KU(4P%]G5+HS9^OSM&9Y2@U"4O^84#H
M`.B4CL!I#M7A=%0X0YAV+D4Z#3^6E7><NJCWUZQCKQK<)+EX0<;93%]R34/+
MWY<$G*R<I-PI-C-10&KEC`C2OQ"S;K%`PU]FO9RMG%)G^3HOU*RM%&VE"0V3
MK(#6-5Q5@51Q_B_V!YUM56I;BBXD2!4HD@]3X^,8CX%>.._.,^?\]Y_RM>D)
M>5Q92<R!;>^TH"BM'-)U8%YD')A44WF7.@EZ4IMUMN1>3:;,,:M>-V9A3-';
MT24#]*C*0GXRUC7\?<9U>*93=,DN]4*BIKUC9IJA,R3+7OIT\(U!GO$!RML+
MD_DK+?&KDHCC&VLG2\D^>S1QWW9'L)C;]7%*@<Y5'O:-NV&`2CUI33"HN;<1
MJ\)I,;RZTBN?HFDI0/X/EZ&4+RNX-R^CSBKR7$KU^AIZQU2U@IW*.[J`9B7^
M$9@XV^(&]\+<S+3Y.WKG9;,#.VFTRJN-TLU%KCD):9B%6*CH7BRYMB3=VN)R
M%V]`*&N<RKFZW9#@#F'62V_;AN^E&B=OA\1&\Q7@^NL6?#,KS<UW%PM2_J&9
M!G.8\!X",T\E?&]>7)7F_B+DI/9%C28XQ*1FA'V&O'=UVJDFY))/"`[[X`7O
M2R950'9TI37/X;RC38AQW68BU3?_`'*Q*DJ<]AZ3]T=%F7$]3E'(5MS%ZI'Z
M6@(4AOV@=9_&-V^:F"+KY.<;\DX*M&ZVUE2&0XTD"_N!VS%ZFC#K*%5>HE;E
M51$XK&2('0P=-</A%]I\4RFWY34-^<FC>#FS^:0.D=QG>.NYABE?BS3GD_JV
M/+W]93(,^WAK&!^)?!6;XL<,;OXUPE\L7M[74I><H:_$HP4$49RZ6;9LF[,R
M[PG,FR%L`@7?[1ZZZ/.>01FN:#+*ME0I&RC:W.<DH)(`^,:+",".&89_:U,\
ME56L**G0)34K0J(]T6=XTO'2_P"!S/)SB?OUED&Y<CRA'KB7:Q9HP&34KQ1^
M+(R9EUQ.!W:QCB-0ZCKV<H\IJY&<HTIIRU24R`$I^`3/\HUG%7%:.-F:TIJ?
M/J*I>XJ/;4G_`!BSN'OC"DN.G+/+O*.^<ELLBR600N$8*+3AC,5K><3=TKS:
M3DSLSE?Z@S2-7%H%"E^'6?,>5U91A5'AU!3J::HTA*IGZI#]\XQ8KQ33X]FE
M=FU:_P"=6U:P4R$MHE*7MC7#+?A:R++\E;JSQ@WD])8D->LV]F)$S..57GXH
MTPX4<3+9C)@Y()FKHZE2E`H;:!KK;+SK0T^(,8MD%J;K/TZ0$;Q-/RB29CO'
M)7S@ZZ5.6.9-CUX70J>)\S8/G*5&:@E4_EBY,9>$9OCSD[C/D-(<@9Z_1L.4
MA+CE(R\F"TK.7'<\4<ZBDFM-*N@!%)14]4DNV()A7J-=8+OS[473#'\5IZ!F
MDHW9B;20D!/AXZ]XK9O3U1V[,V<MK+E5UM:U(R?<*YD=.W;MX0_;X:>H?+[_
M`&5_174<_P!.UMVZRV_E.<21G$4W^9"AID)WC%/"=48&E^M$35,*#>11CH]0
M>GR$57*8H`/^+4UO2&]3JJ[JTN1?4&R!WEJ#\!$'?613O_I;54I)0TVE[YNV
M[Y2!KI-4I2[Q&"^H7H(=TP`;U#H`#7\*:G2:9@]4B/GZJY5ZVO)4ZKRCVTE^
M$HH1=5,HD(<2E-U$``M!_+TT"F82))2`(M:KZQE`;:<*4`Z#3O\`".Q`RGPB
M7<8$C`<"=1`!]H]/0=>>J0A)"@G7Q\(OIJFJ+B6QN<;"BK;VGUGI&R'&+DM?
M?%7,43F_&<+:<U=T'#SL*S:7HP<OXI@A/(((/9)%!JX:JF?I%0**0@;X1]FE
MYR#@5%G-E%EKWG&[<5I4L(,B=NO[3AJ<?<H7?$<E-_I6$+J&FU`;A/8"!/02
M)GX#72+=O2Z\D\F\R7%=S^.<W;DC*]T&EUH6V6+MPL]E'W8:D18,"]]XBS#M
M%*)S;@3#J/36:BH\<P#'6J1RH#%JI6P`5$`R'?MN/NC%<*S+N2\G=N2DK=K*
MI_<EIH$A1,I!74M@Z":M!$J3QE>'6%PN>'SER?AH>ZLGJ(,Y"S[$62^X0>/0
M.0K@KQ^8QA;O[G`QJ"8/V21/@$F\*Z@WS%SU<,BJEV/%W7FK+,I4I.GFB<IG
M28$O;$]>&^!*7&6D7W*6F7+R0%)0H;@SI](GU/MB0@1LA0!23*0H`4I4P+M(
M!2^A2E"@%*%.@!T#4;UJV*GU<_/7K$GDJ0MO81\G3\.DH7Q<?CAP/=?+V$YD
M7++Y`E\KP,K!R,.R>2C):U&2EOE7+#H(QX1@+D08@X/M_;=*Z85)R;DE%ASF
M#TVQ-BJ-V](`F2OJHF<YZ0LJ[BS&+AFS.>50>7?F"G:KJF2/I3TE(?L88>=N
MB<1$Z93"-!&OM$/0?RZ7Y0DJ"R/F'2&:25)V'5'A%001+\J90Z4Z5]/Z=6I:
M;29@03,MO:*"W1,-3)E$?3K7T#\^K@A(7Y@'S@=8%'<G8K5,<NRD!@-L+N`*
M`/N#]&J)0A,]HE,S/OBA$R">HBG92Z?`7H->O7K[^NKBD'K`=3,]8J*28^I"
MZM\M&FG2#Q]L`))E&I2``_A7_EJ]1W#:K410``S'6.8E*(4$*AH`">D5_P`8
MIM+4#4Z@%`'\-6[$E6Z7S16>DNT4[9.OPA\0U'\1]^JE(.IZQ0"6@[Q3M)UK
ML"H!3\VK?+1UEK.*S/X13LI4IL+2M?SZN``Z03[QR!,@#N`H5I2OX#JO5.P_
M1X10ZJW'ZH.V3TVAZ;?^VM:?DKHBDA"W_)YPD/S:X\N[,@W:$??]I/R718KI
M<@"DO)-@WN(A8_04D98B94Q,`A2G4=,WB+.QQYE[=WJ-QMBI)<">LIZGV@0K
M.8N/!R5A[UC:4E%</F;4H3`4.GM$00,JX,RWA">E;;RI8-S6=(PSQ9BZ7E8>
M00AUE43B3N,IH[<L8Z15*`&*)%3=!U].<>SW'LHHT5MJJ&5I<$]N].X3\1.8
M_"/E)E/&N48A<G:"[4SX;:G\X0HI5+N"`=(Q"#R.$.LG&!T'_P!P:>M:4IWM
MP#KI57&G3]2D@?\`N'_&.4;LU<\C>VA4ST!!_=%\6I:%X7.[;IVE:]RW29<Y
M4]EMV],S^X3=!(/VED\]H^OH'MUJ+I?[32H#E94L-L`$DJ<2GIX3($=#8,7R
M1ZM0;?3/K45`$!M1G,:SD#\(:/Q8\./++D3+Q4I<4`IB#'3Y8POKFNQ!5&24
M:!M$080@[7Y')@-\/>2`M?72(S3U%X7CB7*6WDUM=MD$H(*0KM-727CK$A,"
M],V<WRX)N=T6BCMREZ[DG<4CV2_")67#?QI\>.&<:W=6;")71D$S9-*1R'<K
M1LXFE5>AE18$!,R$:F*E:=H"'I[=0GSCDW),[J5+NCI113)2TDG:/#WQ.[`^
M+L5P"G`M+"37&6YU0&XGO+P]D,,*00+M,.[WU]M>H_UZ7'SCH1.&0=29](KM
MH%"_#TZ4_OKJ[^+<>L6R^60TCH,WJ<B@*&`Q3%$?00,`>H#7WAK$&AYI<).O
M:+MR]@0#H/SCZ=98I!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@CB
M>FT:[:?]7I_;JQS;L._Z8J-T_D^J,(9E_@!^[Y?]P`8N&VMRG8#*XV^$3OV_
M%].-R@+?=3]3XM;2Q??/,/V#]7Y^G_3W]>WTQI+Q]C\D_??T_D[3/S9=-9]>
MW6-'TA\07<^7A+W.X/S'QA3?N]FXGOTQW?\`S#Y?]4W*4A.85TE[X5#'_A+S
M/Z?V[=N/\O6?L$;?85_VK5'_`&_AA,!VGI_"\;5$W;VCW/\`X^`#MV?-[*>N
MN%O']W^6K[]^N\C_`.3?+K_FTZPR++_:$Q]A_1[])>7MGTTZ:](V+';^RK6N
M\*;JUK^?KKF6?+D=L_\`5U^$=6?\W7V1]&O1%L&B"#1!!H@@T00:((-$$&B"
:#1!!H@@T00:((-$$&B"#1!!H@@T00:((_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
